
|Videos|January 25, 2022
Dr. Albala on the recent CMS change for Rezum water vapor therapy
Author(s)Urology Times staff
“I think this really now suggests that Rezum is a financially viable procedure across these different treatment settings…the reimbursement now is really quite favorable,” says David M. Albala, MD.
Advertisement
In this video, David M. Albala, MD, discusses the recent change made by the Centers for Medicare & Medicaid Services regarding Rezum water vapor therapy. This new change allows for more financial coverage for patients with benign prostatic hyperplasia (BPH) who seek this treatment. Albala is a urologist at Associate Medical Professionals and chief of urology at Crouse Hospital in Syracuse, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
2
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care
5










